International Journal of Advanced Engineering Research and Science (IJAERS)
Peer-Reviewed Journal
ISSN: 2349-6495(P) | 2456-1908(O)
Vol-12, Issue-10; Oct, 2025
Journal Home Page Available: https://ijaers.com/
Article DOI: https://dx.doi.org/10.22161/ijaers.1210.1

Advances in Nanoplatform Design and Theranostics for HNC via the Tumor Microenvironment

Ngwu Chukwuebuka Vitalis[1], Ying Wang[1*], Afreh Paul[2], Anidobu Chinaecherem Grace[3]

[1]College of Artificial Intelligence, Taiyuan University of Technology, Taiyuan, Shanxi Province, China.
[2]College of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, Shanxi Province, China.
[3]Department of Science Education, Nnamdi Azikiwe University Awka, Anambra State, Nigeria.
[*]Ying Wang: (Corresponding Author) wangying03@tyut.edu.cn

Received: 25 Aug 2025,
Received in revised form: 23 Sep 2025,
Accepted: 27 Sep 2025,
Available online: 07 Oct 2025

***Keywords*— Head and neck cancer; Tumor microenvironment; Nanoplatform; Nanotheranostics; Imaging; Targeted therapy.**

***Abstract*—** *Head and neck cancer (HNC) accounts for approximately 930,000 new cases and 470,000 deaths annually, with squamous cell carcinoma (HNSCC) of the upper aerodigestive tract representing the dominant histology. Tobacco use, alcohol consumption and high-risk human papillomavirus infection are the principal risk factors. Standard-of-care modalities such as surgery, radiotherapy, chemotherapy and photodynamic therapy frequently fail in advanced disease because of off-target toxicity and inherent or acquired resistance. Recent insights into the tumor microenvironment (TME) characterized by hypoxia, acidic pH, extracellular-matrix remodeling and immunosuppression have revealed actionable therapeutic targets. This review synthesizes how nanotechnology exploits these TME features to enhance HNC diagnosis and treatment. We first delineate the unique TME landscape of HNSCC and then classify TME-responsive nanoplatforms according to their design principles: pH, redox, enzyme or hypoxia-triggered release; active targeting of overexpressed receptors; and multimodal theranostics. Subsequent sections evaluate diagnostic applications (MRI, CT, PET, optical and molecular imaging) and therapeutic strategies, including chemotherapy delivery, immunomodulation and combination regimens. Finally, we address translational bottlenecks biocompatibility, manufacturing scalability, tumor heterogeneity, regulatory complexity and propose precision-nanomedicine solutions. Pre-clinical studies demonstrate that TME-activated nanoplatforms achieve superior tumor accumulation, reduced systemic toxicity and integrated imaging-therapy functions. Multifunctional nanocarriers that co-load chemotherapeutics, photosensitizers and immune checkpoint inhibitors further exhibit synergistic anti-tumor activity. Although challenges related to biodistribution, batch-to-batch*

reproducibility and patient stratification persist. Interdisciplinary efforts spanning materials science, oncology and regulatory science are poised to accelerate the clinical translation of TME-focused nanotheranostics toward individualized HNC management.

Graphical abstract



@BioRender.com

I. INTRODUCTION

Head and neck cancer (HNC) is the seventh most common malignancy worldwide, encompassing tumors of the larynx, pharynx and oral cavity [1]. Each year it accounts for approximately 930,000 new cases and 470,000 deaths [2]. Roughly 90% of these lesions are mucosal squamous cell carcinomas (HNSCC) [3]. Major risk factors include tobacco use, alcohol consumption and high-risk human papillomavirus infection; the latter is particularly relevant to oropharyngeal tumors. Despite therapeutic advances, five-year survival for advanced HNSCC remains below 50% [3].

Standard-of-care modalities such as surgery, radiotherapy, chemotherapy and photodynamic therapy [4] are limited by systemic toxicity and off-target effects [5]. Late diagnosis, intrinsic resistance and post-treatment relapse further compromise efficacy [5]. Cisplatin-based regimens, for example, frequently induce nephrotoxicity and ototoxicity [6]. These shortcomings have intensified interest in tumor targeted nanotechnologies. Engineered nanoparticles offer tumor specific delivery, multimodal therapy and reduced systemic exposure [7]. Recent advances include TME-responsive bio-nanocomposites that exploit microenvironmental cues for precision treatment.

Head and neck TME is a highly heterogeneous ecosystem composed of malignant cells, cancer-associated fibroblasts, immune infiltrates, a leaky vasculature and a dense extracellular matrix [8]. Bidirectional crosstalk continuously reshapes this milieu: hypoxic tumor cells up-regulate pro-invasive stromal genes, while CAFs secrete cytokines and matrix proteins that facilitate invasion [9].

Nanotechnology provides versatile solutions [10]. Stimuli responsive platforms achieve tumor specific drug release by exploiting pH sensitive linkers, redox labile bonds or

enzyme cleavable matrices [11]. Functional additives such as photosensitizers, metallic or magnetic cores, further enable imaging and combinatorial therapy [12]. Surface functionalization (EGFR ligands, folate) mediates active targeting, whereas the EPR effect drives passive accumulation [13]. Multifunctional architectures can co-deliver chemotherapeutics, immunomodulators and imaging agents while navigating biological barriers such as abnormal vessels or dense ECM [14].

Here, we review the state-of-the-art in TME-responsive nanoplatforms for HNC. We first dissect the unique features of the HNC-TME, then classify design strategies that respond to pH, redox, enzymatic activity or hypoxia. Subsequent sections evaluate diagnostic applications (molecular assays and advanced imaging) and therapeutic interventions (chemotherapy, immunotherapy and combination regimens). Finally, we outline translational challenges and future directions. By integrating materials science with tumor biology, TME-activated nanoplatforms promise to transform HNC theranostics.

II. CHARACTERISTICS OF THE TUMOR MICROENVIRONMENT IN HEAD AND NECK CANCER

The tumor microenvironment (TME) of head and neck cancer (HNC) is a multicellular and multifactorial ecosystem that orchestrates tumor growth, invasion and metastasis (Fig. 1) [15]. Although conventional therapies have traditionally targeted malignant cells, accumulating evidence indicates that stromal, immune and extracellular components critically modulate therapeutic efficacy [15]. Head and neck squamous cell carcinoma (HNSCC), which accounts for the vast majority of HNC, displays a heterogeneous TME composed of cancer cells, cancer-associated fibroblasts (CAFs), immune infiltrates and an abundant extracellular matrix (ECM) (Fig. 1) [16]. Single-cell RNA-sequencing studies have revealed pronounced transcriptional, developmental, metabolic and functional heterogeneity among these populations [17]. Consequently, the TME constitutes both a barrier to conventional therapy and an attractive target for next-generation nanomedicine [18].



Fig.1 Cross section of Tumor Microenvironment (TME) in Head and Neck Cancer @BioRender.com

Immunosuppressive infiltrates

HNSCC lesions are densely infiltrated by regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) [19]. These populations express checkpoint ligands (e.g., PD-L1) and secrete inhibitory cytokines such as TGF-β and IL-10, thereby attenuating cytotoxic T-cell activity [20]. Under hypoxia, HIF-1α up-regulation further amplifies PD-L1 expression, enhances EGFR signaling and promotes vascular abnormalities, collectively skewing the microenvironment toward immune tolerance [21].

Aberrant angiogenesis and hypoxia

Neo-angiogenesis in HNSCC is rapid yet chaotic, producing tortuous, hyperpermeable vessels that generate heterogeneous perfusion and widespread hypoxia [22]. Tumor hypoxia is an independent predictor of poor prognosis and is associated with aggressive behavior, chemo and radio-resistance and inferior clinical outcomes [23], [24]. In addition, hypoxia reinforces immunosuppression by recruiting Tregs and MDSCs, thereby complicating therapeutic interventions [24].

Extracellular matrix remodeling

The HNSCC ECM is enriched in collagen, fibronectin and proteoglycans [25]. CAFs and cancer cells continuously remodel this matrix: collagen becomes hyper-cross-linked and fibers align, increasing tissue stiffness (Fig. 2) [25]. Overexpressed matrix metalloproteinases (MMP-2, MMP-9) degrade basement-membrane components, facilitating invasion and metastasis [26]. Paradoxically, the same dense matrix impedes drug diffusion, causing therapeutic agents to become entrapped within the stroma [27].



Fig. 2 Cellular components in TME @BioRender.com

Chronic inflammation

Chronic inflammation driven by tobacco, alcohol, viral infections or tissue trauma is a hallmark of HNSCC [28]. Infiltrating neutrophils, macrophages and other myeloid cells release IL-6, IL-8, TNF-α and macrophage migration inhibitory factor (MIF), which promote angiogenesis, epithelial mesenchymal transition (EMT) and immune evasion [29]. These cytokines also recruit additional suppressive immune cells and remodel the ECM, thereby establishing a self-perpetuating inflammatory niche that sustains tumor progression [29].

III. DESIGN STRATEGIES OF NANOPLATFORMS BASED ON THE TUMOR MICROENVIRONMENT

Recent advances in nanomedicine have generated a diverse arsenal of platforms for head and neck cancer (HNC) (Fig. 3) [30]. These systems can be broadly categorized as metallic, lipid-based, polymeric or inorganic, each engineered to exploit unique features of the tumor microenvironment (TME).

Metallic and inorganic nanosystems

Gold nanoparticles (Au NPs) serve dual roles: upon near-infrared (NIR) irradiation they mediate photothermal therapy (PTT) [31], [32], while their high atomic number enhances radiotherapy via secondary-electron emission [33]. Iron oxide nanoparticles (Fe_3O_4) provide magnetic-hyperthermia and magnetically guided drug delivery [34]. Cerium oxide (CeO_2) NPs protect normal tissues from radiation-induced oxidative injury yet sensitize tumor cells through redox modulation [35]. Gadolinium (Gd) and silver (Ag) NPs generate reactive oxygen species (ROS) to potentiate radiation and induce apoptosis [36], [37]. Gd NPs additionally benefit from low intrinsic toxicity, renal clearance and preferential tumor accumulation via the EPR

effect [38].

Lipid-based nanocarriers

Liposomes and nanomicelles possess a phospholipid architecture that simultaneously accommodates hydrophilic and hydrophobic payloads [39]. Surface PEGylation and active ligands (e.g., anti-EGFR antibodies) prolong circulation and enhance tumor specificity [40], [41]. Clinically, liposomal cisplatin has improved pharmacokinetics and reduced nephrotoxicity in HNC patients [42].

Polymeric and solid-lipid platforms

Poly(lactic-co-glycolic acid) (PLGA) and chitosan NPs offer controlled-release kinetics and excellent biocompatibility [43]. Solid-lipid nanoparticles (SLNPs, 50–1000 nm) encapsulate both hydrophilic and lipophilic drugs within a solid-lipid core, shielding them from degradation and minimizing systemic exposure [44], [45]. Incorporating liquid lipids into the matrix increases drug loading by creating lattice imperfections [46]; SLNPs loaded with andrographolide, for instance, enhance anti-HNC efficacy at reduced doses [47].



Fig.3 Nanoparticle advancements in contemporary HNC treatment @BioRender.com

Mesoporous silica nanoparticles (MSNPs)

MSNPs possess FDA-recognized safety, uniform pore sizes (2-23 nm) and high loading capacity [48]. Surface functionalization enables siRNA or drug co-delivery, pH/redox-responsive release and immune evasion [49]. A single MSNP can simultaneously carry doxorubicin and MDR1-siRNA to overcome chemoresistance while lowering cardiotoxicity [50].

Stimuli-responsive "smart" systems

Third and fourth generation nanocarriers exploit intrinsic TME cues or external triggers for on-demand drug release [51], [52]. pH-sensitive polymers or acid-labile linkers (e.g., hydrazone) disintegrate in the acidic extracellular milieu. Redox-responsive carriers containing disulfide bonds rupture under high intracellular glutathione levels [53]. Enzyme-cleavable coatings (MMP- or hyaluronidase-sensitive) fragment upon contact with overexpressed proteases. Hypoxia-activated prodrugs (nitroimidazoles, quinones) are reduced only under ≤2 % O_2, generating cytotoxic radicals while sparing normal tissue [54]. Combinatorial triggers (e.g., pH + redox) can be integrated for even stricter spatiotemporal control.

Immune-regulating nanoplatforms

Nanoparticles can deliver or modulate immunomodulators directly within the TME. Checkpoint blockade: anti-PD-L1-decorated NPs restore exhausted T cells [55]. TAM/Treg

reprogramming: mannose- or folate-coated NPs deliver CSF-1R inhibitors or siRNA to suppress Tregs and M2-like TAMs. Vaccination: antigen/adjuvant-loaded NPs traffic to lymph nodes, inducing dendritic-cell maturation and cytotoxic T-cell priming. Microenvironment remodeling: $CaCO_3$ NPs neutralize lactic acidosis, while collagenase-loaded NPs degrade dense ECM to enhance immune cell infiltration.

Multifunctional theranostic nanosystems

Advanced platforms integrate therapy and imaging within a single vector. Gold or Gd NPs provide CT/MRI contrast, whereas superparamagnetic iron oxide enables real-time MRI tracking [56]. Composite nanosystems can co-deliver chemotherapeutics, photosensitizers and photothermal agents for triple-combination therapy (chemotherapy + PDT + PTT), as demonstrated with graphene oxide/doxorubicin/protoporphyrin IX nanocomposites. Such theranostic strategies enable image-guided, on-demand therapy and hold promise for precision oncology.

IV. APPLICATIONS OF NANOPLATFORMS BASED ON THE TME IN DIAGNOSIS

4.1 Imaging Diagnosis

Nanoplatforms endow conventional imaging modalities with higher sensitivity, specificity and molecular information.

Magnetic Resonance Imaging (MRI)

Gadolinium-based nanocrystals and superparamagnetic iron oxide nanoparticles (SPIONs) shorten T_1 or T_2 relaxation times and preferentially accumulate in tumors via the EPR effect. Ultra-small $NaGdF_4$ nanocrystals coated with MnO_2 have enabled T_1-weighted hypoxia mapping in HNSCC xenografts [57]. Although still pre-clinical, these agents outperform conventional gadolinium chelates in both relaxivity and targeting specificity.



Fig.4 Magnetic Resonance Imaging (MRI) @BioRender.com

Computed Tomography (CT)

High-atomic-number nanoparticles-gold or bismuth-strongly attenuate X-rays, permitting micro-CT visualization of sub-centimetre HNSCC lesions. Antibody- or peptide-conjugated gold nanoprobes have illuminated occult tumors that were invisible with iodinated contrast [58]. Ongoing work is refining ligand density and renal clearance profiles for clinical translation.

International Journal of Advanced Engineering Research and Science (IJAERS)
Peer-Reviewed Journal
ISSN: 2349-6495(P) | 2456-1908(O)
Vol-12, Issue-10; Oct, 2025
Journal Home Page Available: https://ijaers.com/
Article DOI: https://dx.doi.org/10.22161/ijaers.1210.1



Fig 5. Computed Tomography (CT) @BioRender.com

Positron Emission Tomography (PET)

Radiolabeling nanocarriers with ^{18}F, ^{64}Cu or ^{68}Ga merges the pharmacokinetic advantages of nanoparticles with PET's picomolar sensitivity [59]. Radiolabeled liposomes and polymeric NPs have been used to quantify drug delivery to primary tumors and to detect lymph-node micrometastases [60], [61]. Such nanotracers may soon guide individualized staging and adaptive therapy planning.



Fig. 6 Position Emission Tomography (PET) @BioRender.com

4.2 Optical Imaging

Fluorescence Imaging

Quantum dots, upconversion nanocrystals and dye-loaded polymer NPs provide NIR fluorescence that delineates tumor margins intra-operatively. pH-activatable nanoprobes that "light up" only in acidic TME further improve signal-to-background ratios [62].

Photoacoustic Imaging (PAI)

Gold nanorods, carbon nanotubes and MnO_2-coated nanocrystals absorb NIR light and generate ultrasound waves, yielding high-resolution, non-ionizing images. Hybrid $NaGdF_4@MnO_2$ probes have simultaneously mapped hypoxia by PAI and MRI in HNC models [63].



Fig. 7 Fluorescence Imaging and Photoacoustic Imaging (PAI) @BioRender.com

4.3 Molecular Diagnosis

Biomarker Detection

Gold or copper-oxide nanosensors functionalized with antibodies or aptamers enable femtomolar detection of salivary IL-6, IL-8 and TNF-α-established oral cancer biomarkers [64]. Colorimetric or electrochemical readouts facilitate point-of-care screening.

Genomic Testing

Nanoparticle-augmented PCR, isothermal amplification and nanopore sequencing achieve attomolar sensitivity for circulating tumor DNA (ctDNA). Gold nanocluster probes, for example, have detected single-exon deletions in BRCA1 [65]; analogous strategies are being adapted for TP53 or PIK3CA mutations in HNC [66].



Fig. 8 Biomarker Detection and Genomic Testing @BioRender.com

V. APPLICATIONS OF NANOPLATFORMS BASED ON THE TME IN HNC THERAPY

5.1 Chemotherapy Delivery

Encapsulating cytotoxic agents in liposomes, polymeric micelles or dendrimers increases tumor exposure while sparing healthy tissue. Stimuli-responsive carriers release doxorubicin or paclitaxel preferentially within the acidic, enzyme-rich TME, achieving superior growth inhibition in HNSCC xenografts with fewer systemic side effects. Active targeting via folate, anti-EGFR antibodies or RGD peptides further concentrates the payload at the lesion [67]. Early-phase trials of pegylated liposomal cisplatin and albumin-bound paclitaxel already report improved tolerability in recurrent/metastatic HNC.

5.2 Immunotherapy

Nanoparticles are transforming how immunomodulators reach the tumor:

Checkpoint blockade. Conjugating anti-PD-L1 to polymeric NPs confines antibody activity to the TME, lowering off-target autoimmunity while boosting intratumoral drug levels.

Cytokine delivery. IL-12-loaded lipid nanogels activate local CD8+ T cells without the vascular-leak syndrome seen with free cytokine [68].

Neo-antigen vaccination. PLGA particles co-encapsulating tumor lysates and TLR agonists generate robust, antigen-specific T-cell responses in murine HNSCC.

Microenvironment reprogramming. Acid-neutralizing $CaCO_3$ NPs or collagenase-armed carriers dismantle physical and chemical barriers, enhancing T-cell infiltration and synergizing with adoptive cell therapy.

5.3 Combination & Multimodal Therapy

A single nanocarrier can synchronize chemotherapy, phototherapy and immunotherapy to attack resistant HNC on multiple fronts.

Chemo-phototherapy. Graphene oxide co-loaded with doxorubicin and a photosensitizer eradicates orthotopic tumors under NIR irradiation, overcoming drug efflux [69].

Chemo-immuno. Cisplatin plus a TLR7 agonist delivered in one liposome simultaneously debulks the lesion and licenses dendritic cells, tripling median survival in mice.

Radiosensitization. Intravenously injected gold NPs increase the local radiation dose by ~200%, shrinking hypoxic HNSCC tumors without additional systemic toxicity [70]

Tri-modal platforms. A single hybrid nanocomposite combining cisplatin, a photothermal agent and a PD-L1 siRNA achieved near-complete regression in 80% of animals, whereas any monotherapy failed [71]. Coordinating pharmacokinetics through a unified vector remains a unique advantage of nanomedicine.

VI. CHALLENGES AND PROSPECTS FOR CLINICAL TRANSLATION

6.1 Translational Hurdles

Biocompatibility & Toxicity

Although lipids and FDA-approved polymers are generally safe, residual surfactants, heavy-metal dopants or surface functional groups can trigger complement activation or anti-PEG antibodies [72]. Quantum dots, iron oxides and some up-conversion cores raise additional concerns about renal versus hepatic clearance and potential long-term accumulation in reticuloendothelial organs [73]. Rigorous GLP toxicology in large-animal models (>6 months) and quantitative whole-body autoradiography are now considered essential to map organ distribution and establish no-observed-adverse-effect levels (NOAEL) [74]

Manufacturing & Scalability

Microfluidic or flash-nanoprecipitation methods can narrow size distributions below 10% CV at millilitre scale, yet scale-up to 10-100L batches often compromises morphology and surface ligand density [75]. Hybrid architectures-magnetic core + polymer shell + targeting ligand-require orthogonal conjugation chemistry that is sensitive to pH, ionic strength and shear stress. Continuous-flow manufacturing with in-line PAT (process-analytical technology) is emerging as a GMP-compliant route to maintain batch-to-batch reproducibility [76].

Tumor Heterogeneity

Inter-patient variability in EPR magnitude (2-fold to 10-fold) and receptor expression (EGFR 3–200-fold) means a nanoplatform optimised in one xenograft may underperform in another. Integrating pre-treatment PET/MR imaging or single-cell RNA-seq to stratify patients for high-EPR or high-receptor phenotypes is now being piloted as an adaptive inclusion criterion [77], [78].

TME-Induced Resistance

Dense collagen (>10 mg mL^{-1}) and elevated interstitial fluid pressure (>20 mm Hg) can reduce NP penetration by >80%. Hypoxia-driven HIF-1α signalling further up-regulates ABC transporters and DNA-repair enzymes, counteracting both drug and radiation effects [79]. Combination strategies-co-delivery of ECM-degrading enzymes or HIF-1α inhibitors-are therefore being explored to restore NP diffusion and sensitize resistant cells [80].

Immune Clearance

PEGylation extends circulation half-life from minutes to hours, yet repeated dosing elicits anti-PEG IgM, accelerating blood-clearance (ABC) by 3-5-fold [81]. Zwitterionic polymers, CD47-mimetic peptides or erythrocyte-membrane cloaking are under evaluation to evade opsonization while retaining targeting specificity [82].

Regulatory & Economic Barriers

Multifunctional nanotheranostics occupy a regulatory grey zone spanning drugs, devices and biologics [83]. Each additional modality (imaging agent + drug + ligand) multiplies CMC (chemistry-manufacturing-control) endpoints and requires separate safety packages. Demonstrating superiority over standard-of-care in adequately powered Phase II/III trials can exceed USD 20 million; without compelling overall-survival benefit, reimbursement may be denied [84], [85].

6.2 Future Directions

Precision Nanomedicine

Real-time PET/MR imaging and liquid-biopsy-derived exosomal signatures will enable patient-specific adjustment of ligand density, stimulus threshold or drug-to-carrier ratio.

Imaging techniques (including perfusion MRI) are used in clinical trials to predict nanomedicine accumulation and efficacy, enabling prospective patient stratification [86].

Next-Generation Materials

Enzymatically cleavable peptides and DNA origami scaffolds degrade to non-toxic nucleotides or amino acids, eliminating long-term accumulation concerns. In situ

swelling or charge-reversal systems (e.g., from 20 mV to +10 mV at pH 6.5) are being engineered to enhance diffusion across 100-200 µm tumor rims.[87]

Multimodal Theranostics

Hybrid nano-probes labelled with ^{64}Cu for PET, Gd for T_1-weighted MRI and indocyanine green for NIR fluorescence allow simultaneous whole-body biodistribution and intra-operative margin assessment [88]. Closed-loop feedback algorithms are being developed to modulate PTT laser power or PDT drug-light intervals in real time based on intra-tumoral oxygenation [89].

Cross-Disciplinary Integration

Regulatory science consortia (FDA-NCI Nanotechnology Characterization Laboratory, EMA-IMI) now provide standardized protocols for physicochemical characterization, immunotoxicity and large-animal pharmacokinetics [90].

VII. CONCLUSION

TME-responsive nanoplatforms have emerged as a disruptive strategy to overcome the pharmacological and biological barriers that limit conventional HNC therapy. By harnessing hypoxia, acidic pH, ECM stiffness and immunosuppression as endogenous triggers, these systems simultaneously enhance tumor accumulation, minimize systemic exposure and enable real-time imaging feedback. Although long-term biodistribution, manufacturing reproducibility and patient heterogeneity remain critical hurdles, converging advances in precision imaging, adaptive materials design and regulatory science are accelerating clinical translation. Continued interdisciplinary validation will be essential to transform these pre-clinical successes into personalised nanotherapeutics for head-and-neck cancer.

DATA AVAILABILITY STATEMENT

The authors confirm that all data generated or analyzed during this review are included in this article.

DECLARATION OF COMPETING INTEREST

The authors state that they have no competing financial interests or personal relationships that may have influenced the findings in this paper.

FUNDING

This work was supported by China National Natural Science Foundation (11602159), Natural Science Foundation of Shanxi province (202103021224108), Research Project Supported by Shanxi Scholarship Council of China (2023-072).

REFERENCES

[1] I. El Herch, S. Tornaas, H. N. Dongre, and D. E. Costea, "Heterogeneity of cancer-associated fibroblasts and tumor-promoting roles in head and neck squamous cell carcinoma," *Front. Mol. Biosci.*, vol. 11, June 2024, doi: 10.3389/fmolb.2024.1340024.

[2] "Oral microbiome and risk of incident head and neck cancer: A nested case-control study," *Oral Oncol.*, vol. 137, p. 106305, Feb. 2023, doi: 10.1016/j.oraloncology.2022.106305.

[3] I. El Herch, S. Tornaas, H. N. Dongre, and D. E. Costea, "Heterogeneity of cancer-associated fibroblasts and tumor-promoting roles in head and neck squamous cell carcinoma," *Front. Mol. Biosci.*, vol. 11, June 2024, doi: 10.3389/fmolb.2024.1340024.

[4] "Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer?," *Photodiagnosis Photodyn. Ther.*, vol. 6, no. 1, pp. 3–11, Mar. 2009, doi: 10.1016/j.pdpdt.2009.03.002.

[5] G. Ruiz-Pulido *et al.*, "Nanomaterials for the Diagnosis and Treatment of Head and Neck Cancers: A Review," *Materials*, vol. 14, no. 13, p. 3706, Jan. 2021, doi: 10.3390/ma14133706.

[6] "Cisplatin in cancer therapy: Molecular mechanisms of action," *Eur. J. Pharmacol.*, vol. 740, pp. 364–378, Oct. 2014, doi: 10.1016/j.ejphar.2014.07.025.

[7] G. Ruiz-Pulido *et al.*, "Nanomaterials for the Diagnosis and Treatment of Head and Neck Cancers: A Review," *Materials*, vol. 14, no. 13, p. 3706, Jan. 2021, doi: 10.3390/ma14133706.

[8] I. El Herch, S. Tornaas, H. N. Dongre, and D. E. Costea, "Heterogeneity of cancer-associated fibroblasts and tumor-promoting roles in head and neck squamous cell carcinoma," *Front. Mol. Biosci.*, vol. 11, June 2024, doi:

10.3389/fmolb.2024.1340024.

[9] S. Koontongkaew, "The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas," *J. Cancer*, vol. 4, no. 1, pp. 66–83, Jan. 2013, doi: 10.7150/jca.5112.

[10] S. Malik, K. Muhammad, and Y. Waheed, "Nanotechnology: A Revolution in Modern Industry," *Molecules*, vol. 28, no. 2, p. 661, Jan. 2023, doi: 10.3390/molecules28020661.

[11] W. Zhou, Y. Jia, Y. Liu, Y. Chen, and P. Zhao, "Tumor Microenvironment-Based Stimuli-Responsive Nanoparticles for Controlled Release of Drugs in Cancer Therapy," *Pharmaceutics*, vol. 14, no. 11, p. 2346, Nov. 2022, doi: 10.3390/pharmaceutics14112346.

[12] L. Cheng, C. Wang, L. Feng, K. Yang, and Z. Liu, "Functional Nanomaterials for Phototherapies of Cancer," *Chem. Rev.*, vol. 114, no. 21, pp. 10869–10939, Nov. 2014, doi: 10.1021/cr400532z.

[13] I.-A. Vagena, C. Malapani, M.-A. Gatou, N. Lagopati, and E. A. Pavlatou, "Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives," *Appl. Sci.*, vol. 15, no. 6, p. 3189, Mar. 2025, doi: 10.3390/app15063189.

[14] Y. Li *et al.*, "Overcoming Biological Barriers in Cancer Therapy: Cell Membrane-Based Nanocarrier Strategies for Precision Delivery," *Int. J. Nanomedicine*, vol. 20, pp. 3113–3145, Dec. 2025, doi: 10.2147/IJN.S497510.

[15] S. M. Shamsudeen and S. Annamalai, "TUMOR MICROENVIRONMENT- A REVIEW," *Int. J. Med. Sci. Diagn. Res.*, vol. 4, no. 11, Nov. 2020, doi: 10.32553/ijmsdr.v4i11.708.

[16] C. Hu, Y. Zhang, C. Wu, and Q. Huang, "Heterogeneity of cancer-associated fibroblasts in head and neck squamous cell carcinoma: opportunities and challenges," *Cell Death Discov.*, vol. 9, no. 1, p. 124, Apr. 2023, doi: 10.1038/s41420-023-01428-8.

[17] X. Meng, Y. Zheng, L. Zhang, P. Liu, Z. Liu, and Y. He, "Single-Cell Analyses Reveal the Metabolic Heterogeneity and Plasticity of the Tumor Microenvironment during Head and Neck Squamous Cell Carcinoma Progression," *Cancer Res.*, vol. 84, no. 15, pp. 2468–2483, Aug. 2024, doi: 10.1158/0008-5472.CAN-23-1344.

[18] X. Shao, X. Zhao, B. Wang, J. Fan, J. Wang, and H. An, "Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy," *Theranostics*, vol. 15, no. 5, pp. 1689–1714, Jan. 2025, doi: 10.7150/thno.103636.

[19] "Frontiers | The role of the tumor microenvironment in HNSCC resistance and targeted therapy." Accessed: Sept. 05, 2025. [Online]. Available: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1554835/full

[20] "Regulatory mechanisms of PD-1/PD-L1 in cancers | Molecular Cancer." Accessed: Sept. 05, 2025. [Online]. Available: https://link.springer.com/article/10.1186/s12943-024-02023-w

[21] "EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles," *Int. J. Pharm.*, vol. 592, p. 120082, Jan. 2021, doi: 10.1016/j.ijpharm.2020.120082.

[22] J. Z. Li, W. Gao, J. Y.-W. Chan, W.-K. Ho, and T.-S. Wong, "Hypoxia in Head and Neck Squamous Cell Carcinoma," *Int. Sch. Res. Not.*, vol. 2012, no. 1, p. 708974, 2012, doi: 10.5402/2012/708974.

[23] C. DeJohn, A. Verma, V. K. Vincent-Chong, and M. Seshadri, "Abstract 2388: Non-invasive imaging of hypoxia as a biomarker of immunotherapeutic efficacy in head and neck cancer," *Cancer Res.*, vol. 83, no. 7_Supplement, p. 2388, Apr. 2023, doi: 10.1158/1538-7445.AM2023-2388.

[24] A. Y. Isa, T. H. Ward, C. M. L. West, N. J. Slevin, and J. J. Homer, "Hypoxia in head and neck cancer," *Br. J. Radiol.*, vol. 79, no. 946, pp. 791–798, Oct. 2006, doi: 10.1259/bjr/17904358.

[25] J. Huang *et al.*, "Extracellular matrix and its therapeutic potential for cancer treatment," *Signal Transduct. Target. Ther.*, vol. 6, no. 1, p. 153, Apr. 2021, doi: 10.1038/s41392-021-00544-0.

[26] G. Barillari, "The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process," *Int. J. Mol. Sci.*, vol. 21, no. 12, p. 4526, Jan. 2020, doi: 10.3390/ijms21124526.

[27] E. Henke, R. Nandigama, and S. Ergün, "Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy," *Front. Mol. Biosci.*, vol. 6, Jan. 2020, doi: 10.3389/fmolb.2019.00160.

[28] M. Nigam *et al.*, "Evaluation of the association of chronic inflammation and cancer: Insights and implications," *Biomed. Pharmacother.*, vol. 164, p. 115015, Aug. 2023, doi: 10.1016/j.biopha.2023.115015.

[29] Y. Wen *et al.*, "Chronic inflammation, cancer development and immunotherapy," *Front. Pharmacol.*, vol. 13, Oct. 2022, doi: 10.3389/fphar.2022.1040163.

[30] G. Ruiz-Pulido *et al.*, "Nanomaterials for the Diagnosis and Treatment of Head and Neck Cancers: A Review," *Materials*, vol. 14, no. 13, p. 3706, Jan. 2021, doi: 10.3390/ma14133706.

[31] X. Bai *et al.*, "The Basic Properties of Gold Nanoparticles and their Applications in Tumor Diagnosis and Treatment," *Int. J. Mol. Sci.*, vol. 21, no. 7, p. 2480, Jan. 2020, doi: 10.3390/ijms21072480.

[32] C. Soica *et al.*, "Chapter 5 - Silver-, gold-, and iron-based metallic nanoparticles: Biomedical applications as theranostic agents for cancer," in *Design of Nanostructures for Theranostics Applications*, A. M. Grumezescu, Ed., William Andrew Publishing, 2018, pp. 161–242. doi: 10.1016/B978-0-12-813669-0.00005-1.

[33] A. A. Borran, A. Aghanejad, A. Farajollahi, J. Barar, and Y. Omidi, "Gold nanoparticles for radiosensitizing and imaging of cancer cells," *Radiat. Phys. Chem.*, vol. 152, pp. 137–144, Nov. 2018, doi: 10.1016/j.radphyschem.2018.08.010.

[34] "Magnetic Nanoparticles for Precision Oncology: Theranostic Magnetic Iron Oxide Nanoparticles for Image-Guided and Targeted Cancer Therapy: Nanomedicine: Vol 12, No 1." Accessed: Sept. 05, 2025. [Online]. Available: https://www.tandfonline.com/doi/abs/10.2217/nnm-2016-0316

[35] P. Eriksson *et al.*, "Cerium oxide nanoparticles with antioxidant capabilities and gadolinium integration for MRI contrast enhancement," *Sci. Rep.*, vol. 8, no. 1, p. 6999, May 2018, doi: 10.1038/s41598-018-25390-z.

[36] H. Li, Y. Zeng, H. Zhang, Z. Gu, Q. Gong, and K. Luo, "Functional gadolinium-based nanoscale systems for cancer theranostics," *J. Controlled Release*, vol. 329, pp. 482–512, Jan. 2021, doi: 10.1016/j.jconrel.2020.08.064.

[37] S. H. Lee and B.-H. Jun, "Silver Nanoparticles: Synthesis and Application for Nanomedicine," *Int. J. Mol. Sci.*, vol. 20, no. 4, p. 865, Jan. 2019, doi: 10.3390/ijms20040865.

[38] "Gadolinium-Based Nanoparticles Can Overcome the Radioresistance o...: Ingenta Connect." Accessed: Sept. 05, 2025. [Online]. Available: https://www.ingentaconnect.com/contentone/asp/jbn/2020/00000016/00000001/art00010

[39] E. Beltrán-Gracia, A. López-Camacho, I. Higuera-Ciapara, J. B. Velázquez-Fernández, and A. A. Vallejo-Cardona, "Nanomedicine review: clinical developments in liposomal applications," *Cancer Nanotechnol.*, vol. 10, no. 1, p. 11, Dec. 2019, doi: 10.1186/s12645-019-0055-y.

[40] T. Zheng *et al.*, "Enhanced antiproliferative effect of resveratrol in head and neck squamous cell carcinoma using GE11 peptide conjugated liposome," *Int. J. Mol. Med.*, vol. 43, no. 4, pp. 1635–1642, Apr. 2019, doi: 10.3892/ijmm.2019.4096.

[41] "Novel anti-EGFR scFv human antibody-conjugated immunoliposomes enhance chemotherapeutic efficacy in squamous cell carcinoma of head and neck - ScienceDirect." Accessed: Sept. 05, 2025. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S1368837520301251

[42] "Medicine." Accessed: Sept. 05, 2025. [Online]. Available: https://journals.lww.com/md-journal/fulltext/2018/11160/meta_analysis_of_clinical_trials_comparing_the.32.aspx

[43] X.-Y. Chu *et al.*, "Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel– cholesterol complex," *Int. J. Nanomedicine*, vol. 14, pp. 689–705, Jan. 2019, doi: 10.2147/IJN.S188667.

[44] P. Agrawal, A. Tatode, and M. Umekar, "Solid Lipid Nanoparticle for the Delivery of Docetaxel: A Review," *J. Drug Deliv. Ther.*, vol. 10, no. 5-s, pp. 224–228, Oct. 2020, doi: 10.22270/jddt.v10i5-s.4441.

[45] V. Mishra *et al.*, "Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems," *Pharmaceutics*, vol. 10, no. 4, p. 191, Dec. 2018, doi: 10.3390/pharmaceutics10040191.

[46] R. H. Müller, M. Radtke, and S. A. Wissing, "Nanostructured lipid matrices for improved microencapsulation of drugs," *Int. J. Pharm.*, vol. 242, no. 1, pp. 121–128, Aug. 2002, doi: 10.1016/S0378-5173(02)00180-1.

[47] "Andrographolide-loaded solid lipid nanoparticles enhance anti-cancer activity against head and neck cancer and

precancerous cells - Li - 2022 - Oral Diseases - Wiley Online Library." Accessed: Sept. 05, 2025. [Online]. Available: https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13751

[48] "Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer." Accessed: Sept. 05, 2025. [Online]. Available: https://www.mdpi.com/2079-4991/7/7/189

[49] A. Watermann and J. Brieger, "Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer," *Nanomaterials*, vol. 7, no. 7, p. 189, July 2017, doi: 10.3390/nano7070189.

[50] "Full article: Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment." Accessed: Sept. 05, 2025. [Online]. Available: https://www.tandfonline.com/doi/full/10.2147/IJN.S150610

[51] G. Ruiz-Pulido *et al.*, "Nanomaterials for the Diagnosis and Treatment of Head and Neck Cancers: A Review," *Materials*, vol. 14, no. 13, p. 3706, Jan. 2021, doi: 10.3390/ma14133706.

[52] J. Liang, B. Yang, X. Zhou, Q. Han, J. Zou, and L. Cheng, "Stimuli-responsive drug delivery systems for head and neck cancer therapy," *Drug Deliv.*, vol. 28, no. 1, pp. 272–284, Jan. 2021, doi: 10.1080/10717544.2021.1876182.

[53] "Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review | Journal of Nanobiotechnology." Accessed: Sept. 05, 2025. [Online]. Available: https://link.springer.com/article/10.1186/s12951-024-02859-w

[54] Y. Zeng *et al.*, "Hypoxia-activated prodrugs and redox-responsive nanocarriers," *Int. J. Nanomedicine*, vol. 13, pp. 6551–6574, Oct. 2018, doi: 10.2147/IJN.S173431.

[55] "Regulatory mechanisms of PD-1/PD-L1 in cancers | Molecular Cancer." Accessed: Sept. 05, 2025. [Online]. Available: https://link.springer.com/article/10.1186/s12943-024-02023-w

[56] G. Ruiz-Pulido *et al.*, "Nanomaterials for the Diagnosis and Treatment of Head and Neck Cancers: A Review," *Materials*, vol. 14, no. 13, p. 3706, Jan. 2021, doi: 10.3390/ma14133706.

[57] "Photoacoustic and Magnetic Resonance Imaging of Hybrid Manganese Dioxide-Coated Ultra-Small NaGdF4 Nanoparticles for Spatiotemporal Modulation of Hypoxia in Head and Neck Cancer." Accessed: Sept. 05, 2025. [Online]. Available: https://www.mdpi.com/2072-6694/12/11/3294

[58] R. Popovtzer *et al.*, "Gold Nano-Probes as Targeted CT Contrast Agents for In-vivo cancer Imaging".

[59] R. Chakravarty, S. Goel, and W. Cai, "Nanobody: The 'Magic Bullet' for Molecular Imaging?," *Theranostics*, vol. 4, no. 4, pp. 386–398, Jan. 2014, doi: 10.7150/thno.8006.

[60] K. J. Harrington *et al.*, "Effective Targeting of Solid Tumors in Patients With Locally Advanced Cancers by Radiolabeled Pegylated Liposomes," *Clin. Cancer Res.*, vol. 7, no. 2, pp. 243–254, Feb. 2001.

[61] "Radionuclide-labelled liposomes—A new lymph node imaging agent," *Int. J. Nucl. Med. Biol.*, vol. 6, no. 2, pp. 75–83, Jan. 1979, doi: 10.1016/0047-0740(79)90001-9.

[62] Z. Xu *et al.*, "Dual Tumor-Selective β-Carboline-Based Fluorescent Probe for High-Contrast/Rapid Diagnosis of Clinical Tumor Tissues," *Mol. Pharm.*, vol. 21, no. 1, pp. 152–163, Jan. 2024, doi: 10.1021/acs.molpharmaceut.3c00689.

[63] "Photoacoustic and Magnetic Resonance Imaging of Hybrid Manganese Dioxide-Coated Ultra-Small NaGdF4 Nanoparticles for Spatiotemporal Modulation of Hypoxia in Head and Neck Cancer." Accessed: Sept. 06, 2025. [Online]. Available: https://www.mdpi.com/2072-6694/12/11/3294

[64] "Nanomaterial Biosensors in Salivary Diagnosis of Oral Cancer: A Scoping Review | Cureus." Accessed: Sept. 06, 2025. [Online]. Available: https://www.cureus.com/articles/253530-nanomaterial-biosensors-in-salivary-diagnosis-of-oral-cancer-a-scoping-review#!/

[65] Y. Zhang, M. Li, X. Gao, Y. Chen, and T. Liu, "Nanotechnology in cancer diagnosis: progress, challenges and opportunities," *J. Hematol. Oncol.J Hematol Oncol*, vol. 12, no. 1, p. 137, Dec. 2019, doi: 10.1186/s13045-019-0833-3.

[66] Y. Zhang, M. Li, X. Gao, Y. Chen, and T. Liu, "Nanotechnology in cancer diagnosis: progress, challenges and opportunities," *J. Hematol. Oncol.J Hematol Oncol*, vol. 12, no. 1, p. 137, Dec. 2019, doi: 10.1186/s13045-019-

0833-3.

[67] "Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting." Accessed: Sept. 06, 2025. [Online]. Available: https://www.mdpi.com/2079-4991/15/3/158

[68] "Advances in engineering and delivery strategies for cytokine immunotherapy: Expert Opinion on Drug Delivery: Vol 20, No 5." Accessed: Sept. 06, 2025. [Online]. Available: https://www.tandfonline.com/doi/abs/10.1080/17425247.2023.2208344

[69] "Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance: Expert Opinion on Drug Delivery: Vol 19, No 4." Accessed: Sept. 06, 2025. [Online]. Available: https://www.tandfonline.com/doi/abs/10.1080/17425247.2022.2041598

[70] "Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo." Accessed: Sept. 06, 2025. [Online]. Available: https://www.mdpi.com/2072-6694/15/23/5697

[71] W. Xu *et al.*, "Chemical Design of Magnetic Nanomaterials for Imaging and Ferroptosis-Based Cancer Therapy," *Chem. Rev.*, vol. 125, no. 4, pp. 1897–1961, Feb. 2025, doi: 10.1021/acs.chemrev.4c00546.

[72] D. Sivadasan, M. H. Sultan, O. Madkhali, Y. Almoshari, and N. Thangavel, "Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform—A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications," *Pharmaceutics*, vol. 13, no. 8, p. 1291, Aug. 2021, doi: 10.3390/pharmaceutics13081291.

[73] C. F. G. C. Geraldes, "Imaging Applications of Inorganic Nanomaterials", Accessed: Sept. 06, 2025. [Online]. Available: https://books.rsc.org/books/edited-volume/841/chapter/586190/Imaging-Applications-of-Inorganic-Nanomaterials

[74] G. A. Parker, "Introduction to Toxicologic Pathology," in *Toxicologic Pathology for Non-Pathologists*, T. J. Steinbach, D. J. Patrick, and M. E. Cosenza, Eds., New York, NY: Springer, 2019, pp. 1–44. doi: 10.1007/978-1-4939-9777-0_1.

[75] T. Chen, Y. Peng, M. Qiu, C. Yi, and Z. Xu, "Recent advances in mixing-induced nanoprecipitation: from creating complex nanostructures to emerging applications beyond biomedicine," *Nanoscale*, vol. 15, no. 8, pp. 3594–3609, Feb. 2023, doi: 10.1039/D3NR00280B.

[76] A. Shahiwala, "Commercial Production of Liposomes: Advancements and Innovation in Manufacturing Processes, Quality Assurance, and Control," in *Commercial Scale Production of Nanomedicines*, CRC Press, 2025.

[77] Y. Shi, R. van der Meel, X. Chen, and T. Lammers, "The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy," *Theranostics*, vol. 10, no. 17, pp. 7921–7924, June 2020, doi: 10.7150/thno.49577.

[78] Y. Zhang *et al.*, "Single-cell RNA sequencing in cancer research," *J. Exp. Clin. Cancer Res.*, vol. 40, no. 1, p. 81, Mar. 2021, doi: 10.1186/s13046-021-01874-1.

[79] A. Turdo, M. Todaro, and G. Stassi, "Targeting Cancer Stem Cells and the Tumor Microenvironment," in *Cancer Stem Cells: Emerging Concepts and Future Perspectives in Translational Oncology*, S. Babashah, Ed., Cham: Springer International Publishing, 2015, pp. 445–476. doi: 10.1007/978-3-319-21030-8_16.

[80] S. K. Debnath, M. Debnath, A. Ghosh, R. Srivastava, and A. Omri, "Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications," *Pharmaceuticals*, vol. 17, no. 10, p. 1389, Oct. 2024, doi: 10.3390/ph17101389.

[81] J. S. Suk, Q. Xu, N. Kim, J. Hanes, and L. M. Ensign, "PEGylation as a strategy for improving nanoparticle-based drug and gene delivery," *Adv. Drug Deliv. Rev.*, vol. 99, no. Pt A, pp. 28–51, Apr. 2016, doi: 10.1016/j.addr.2015.09.012.

[82] J. Lu *et al.*, "Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials," *Exploration*, vol. 3, no. 1, p. 20220045, Jan. 2023, doi: 10.1002/EXP.20220045.

[83] J. Paradise, "Regulating Nanomedicine at the Food and Drug Administration," *AMA J. Ethics*, vol. 21, no. 4, pp. 347–355, Apr. 2019, doi: 10.1001/amajethics.2019.347.

[84] "ClinicalPath_Fierce_Whitepaper_Tackling-Cancer-Therapy-Clinical-Trial-Management-Challenges.pdf." Accessed: Sept. 26, 2025. [Online]. Available: https://assets.ctfassets.net/o78em1y1w4i4/1sQ6FxGyH5v

nOkc0Ozt84o/93a4512a7ba2937b919192614a8cf656/ClinicalPath_Fierce_Whitepaper_Tackling-Cancer-Therapy-Clinical-Trial-Management-Challenges.pdf

[85] G. Chauca Strand, N. Johansson, N. Jakobsson, C. Bonander, and M. Svensson, "Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?," *Clin. Drug Investig.*, vol. 43, no. 8, pp. 621–633, 2023, doi: 10.1007/s40261-023-01285-4.

[86] A. Dasgupta, I. Biancacci, F. Kiessling, and T. Lammers, "Imaging-assisted anticancer nanotherapy," *Theranostics*, vol. 10, no. 3, pp. 956–967, Jan. 2020, doi: 10.7150/thno.38288.

[87] "Charge-Reversal Nano-Drug Delivery Systems in the Tumor Microenvironment: Mechanisms, Challenges, and Therapeutic Applications." Accessed: Sept. 06, 2025. [Online]. Available: https://www.mdpi.com/1422-0067/25/18/9779

[88] Y. Li *et al.*, "A smart and versatile theranostic nanomedicine platform based on nanoporphyrin," *Nat. Commun.*, vol. 5, no. 1, p. 4712, Aug. 2014, doi: 10.1038/ncomms5712.

[89] A. Langley *et al.*, "Heterogeneous tumor blood oxygenation dynamics during phototherapy deciphered with real-time label-free photoacoustic imaging," *Npj Acoust.*, vol. 1, no. 1, p. 9, June 2025, doi: 10.1038/s44384-025-00012-x.

[90] M. J. Salgueiro and M. Zubillaga, "Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy—Implications for Radiopharmaceutical Repurposing (Beyond Oncology)," *Pharmaceutics*, vol. 17, no. 9, p. 1159, Sept. 2025, doi: 10.3390/pharmaceutics17091159.